According to the meta-analysis (Figure 7), immune checkpoint drugs vs. chemotherapy extended the PFS of NSCLC patients with EGFR wild-type (HR, 0.44; 95% CI, (0.35, 0.56)). This evidence concerns the gene EGFR and non-small cell lung carcinoma.